Cover Image
市場調查報告書

Simponi(潰瘍性大腸炎)- 預測與市場分析

Simponi (Ulcerative Colitis) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 300576
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
Simponi(潰瘍性大腸炎)- 預測與市場分析 Simponi (Ulcerative Colitis) - Forecast and Market Analysis to 2022
出版日期: 2014年02月28日 內容資訊: 英文 46 Pages
簡介

2012年到2022年潰瘍性大腸炎(UC)治療藥市場,預測將在Johnson & Johnson(Simponi)、武田藥品工業(Entyvio)的加入下大幅成長,主要國家(美國、歐盟五國、日本、加拿大)預計接受生技藥品治療的患者數將會增加。此外由於UC的暢銷藥物(Remicade,Humira)在美國專利到期,生技仿製藥的發售有影響市場的可能性。

本報告提供UC治療藥物Simponi的調查分析,提供疾病概要和治療指南,競爭情形,產品資訊,及主要國家的銷售額預測等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 症狀

第4章 疾病的管理

  • 診斷和治療概要

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 Simponi(golimumab)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表

目錄
Product Code: GDHC347DFR

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Simponi is a chimeric human-mouse IgG1? mAb that binds with high affinity to TNF-a and is administered subcutaneously with an injectable pen or a prefilled syringe. It is marketed by Janssen as a patient-friendly alternative treatment to Remicade. The benefit that Simponi offers is the SC administration, which means there are no injection site-related adverse reactions.

Scope

  • Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Simponi including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Simponi for the top eight countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Canada.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Simponi performance
  • Obtain sales forecast for Simponi from 2012-2022 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Canada)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
    • 3.2.1. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Simponi (golimumab)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed UC Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. Primary Research. Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Author
    • 7.7.2. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Genetic Factors That Confer a Predisposition to UC
  • Table 2: Typical Symptoms of UC
  • Table 3: Truelove and Witts UC Severity Index
  • Table 4: UCDAI
  • Table 5: Treatment Guidelines for UC Used in the 10MM
  • Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013
  • Table 7: Leading Treatments for UC, 2014
  • Table 8: Product Profile - Simponi
  • Table 9: Simponi SWOT Analysis, 2014
  • Table 10: Global Sales Forecasts ($m) for Simponi, 2012-2022
  • Table 11: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 2: UC Disease Management Flowchart
Back to Top